EPS for AveXis, Inc. (AVXS) forecasted at $-1.95

April 17, 2018 - By Eula Gilbert

On May, 10 AveXis, Inc. (NASDAQ:AVXS)’s earnings release is awaited by WallStreet, as reported by RTT. The earnings per share diference is $0.88 or 82.24 % down from last years number. Previous year: $-1.07; Analysts forcast: $-1.95. -23.53 % EPS growth is what analysts predict. $-2.55 earnings per share was revealed for last [previous quarter]. AVXS reached $210.76 on during the last trading session after $0.38 change.AveXis, Inc. has 1.08M shares volume, 33.00% up from normal. AVXS is uptrending and has moved 59.28% since April 17, 2017. AVXS outperformed by 47.73% the S&P500.

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases.The firm is worth $7.76 billion. The Company’s initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.Currently it has negative earnings. The firm also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.

AveXis, Inc. (NASDAQ:AVXS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.